91ÌÒÉ«ÊÓƵ

Independent Data Safety Monitoring Board (DSMB) recommends
to continue HERACLES study without modification.

Lyon, France, February 5, 2019 – 91ÌÒÉ«ÊÓƵ announced today that its independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company’s ongoing Phase II HERACLES study () with lead biotherapeutic MaaT013 in steroid-resistant, gastrointestinal-predominant, acute Graft-versus-Host-Disease (SR GI aGvHD) after allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT). The DSMB confirmed the absence of safety issues during the trial from initiation until the first safety evaluation milestone of five patients treated. Enrollment is on schedule with sites recruiting in France and Poland. Additional sites in three other European countries are scheduled to begin recruitment in early 2019. MaaT013 is the first full-ecosystem, off-the-shelf biotherapeutic emerging from 91ÌÒÉ«ÊÓƵ’s Microbiome Restoration Biotherapeutic (MMRB) platform and has been granted orphan drug designation by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).The HERACLES study is a multi-center, single-arm, open-label study, enrolling 32 patients to evaluate the safety and efficacy of 91ÌÒÉ«ÊÓƵ’s lead microbiome restoration drug candidate MaaT013 in steroid-resistant aGvHD patients. Acute GvHD is a serious, often fatal syndrome typically involving the gut, skin, and liver. Treatments up to now focused largely on suppressing the immune reaction induced by the donor cells derived from the hematopoietic stem cell graft against the host and have remained clinically unsuccessful in most cases, with mortality rates around 80% after twelve months in steroid-resistant cases. Prior to stem cell transplantation, patients who develop aGvHD have been treated with intensive chemotherapy and antibiotics, which are known to severely impact the gut microbial composition.

About MaaT013

MaaT013 is the off-the-shelf, reproducible, enema formulation manufactured using 91ÌÒÉ«ÊÓƵ’s integrated MMRB platform. The product has a stability of up to 18 months and is characterized by a high diversity and consistent richness of microbial species derived from pooled healthy donors and manufactured at the company’s centralized European cGMP production facility. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and is already being administered in compassionate use.

About 91ÌÒÉ«ÊÓƵ

91ÌÒÉ«ÊÓƵ, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, 91ÌÒÉ«ÊÓƵ has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 91ÌÒÉ«ÊÓƵ benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.